慧博雲通(301316.SZ):目前的研發主要面向雲計算、大數據、物聯網、人工智能等新興領域
格隆匯6月1日丨慧博雲通(301316.SZ)在5月31日(星期三)下午15:00-17:00業績説明會上表示,公司未來的開發方向主要集中在金融科技解決方案、智能操作系統軟件技術和基於人工智能的大數據技術等三個領域。公司計劃加大在這些領域的研發創新投入,以構建核心競爭力並滿足市場需求。公司目前的研發主要面向雲計算、大數據、物聯網、人工智能等新興領域,包括雲計算微服務、AI數據平台、數據中台、金融科技等。通過擴建軟件技術研發中心,有利於提升公司在新興領域的研發能力與技術水平,推動相關技術研發成果轉化為產品及服務方案,進一步提高公司在軟件技術服務領域的業務能力和綜合競爭力。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.